We assessed the effect of influenza vaccination on plasma levels of human immunodeficiency virus type 1 (HIV-1) RNA and the impact of age, plasma HIV-1 RNA level, CD4 cell count, and anti-HIV therapy on immune response. Forty-nine adults (mean age, 38.7 years; mean CD4 cell count {SD, 190 { 169/mL; mean plasma HIV-1 RNA level { SD, 154,616 { 317,192 copies/mL) were immunized. Elevations of §0.48 log in plasma HIV-1 RNA levels occurred in two (4%) of 49 subjects within 4 weeks of vaccination. A fourfold or greater increase in antibody titer occurred in 13 (45%) of 29 subjects, correlating directly with CD4 cell count (P Å .002) and inversely with plasma HIV-1 RNA level (P Å .034). By multivariate analysis, CD4 cell count was a stronger predictor of antibody response than was plasma HIV-1 RNA level. We conclude that increases in plasma HIV-1 RNA levels following influenza vaccination are rare and transient and that antibody response is impaired with CD4 cell counts of õ100/mL and plasma HIV-1 RNA levels of ú100,000 copies/mL. Prospective trials are needed to evaluate the impact of highly active therapy on immune response after vaccination.
A number of investigators have reported significant increases differences in vaccine type and in the immunogenicity of vaccine antigens, variations in observation periods, relatively small in plasma levels of HIV type 1 (HIV-1) RNA following vaccination of HIV-infected patients against influenza, pneumococ-sample sizes, and lack of stratification by CD4 lymphocyte count, plasma HIV-1 RNA level, or concurrent administration cal infection, and tetanus, which raises questions about the advisability of routinely vaccinating these patients [1 -12] .
of antiretroviral therapy. The present study was designed to further investigate the Threefold to 586-fold elevations of plasma HIV-1 RNA levels have been reported, with levels returning to baseline as early effect of influenza vaccination on plasma HIV-1 RNA levels and to explore the impact of age, plasma HIV-1 RNA level, as 2 weeks following immunization [2, 3] . Other investigators have observed no effect of vaccination on HIV levels [13 -22] .
CD4 lymphocyte count, and concurrent antiretroviral therapy on immune response and postvaccination viral load. See editorial response by Couch on pages 548-51.
Possible explanations for these discordant observations include
Methods occurrence of acute illnesses during the postvaccination period, Subjects HIV-infected adults receiving primary care in an outpatient for the development of any postvaccination plasma HIV-1 RNA value §0.48 log (threefold or more) above the baseline value. Subjects were immunized with the trivalent influenza virus Mean log plasma HIV-1 RNA values at baseline and at 2 weeks vaccine (Wyeth-Ayerst Laboratories, Philadelphia) for the were compared by using the paired sample t test, and data 1994 -1995 influenza season; the vaccine contained antigens across all five time points were analyzed through repeated A/Texas/36/91 (H 1 N 1 ), A/Shangdong/09/93 (H 3 N 2 ), and B/ measures analysis of variance. To allow calculation of mean Panama/45/90. Plasma specimens were drawn in EDTA-convalues, plasma samples with HIV-1 RNA levels below or above taining vials before vaccination and at subsequent regular clinic the limits of detection were assigned values of 10,000 and visits (average number of visits per patient, 2.7; range, 1 -4) 1,600,000 copies/mL, respectively. during the next 20 weeks. Specimens were centrifuged within
The second set of analyses focused on examining factors 3 hours of collection, stored at 070ЊC, and batch-tested at associated with antibody response. The influence of antiretrovi-Chiron Corporation (Emeryville, CA) by using a branched ral therapy, age, plasma HIV-1 RNA level, and CD4 cell count DNA assay with a sensitivity of 10,000 copies/mL and an on antibody response was analyzed by using Fisher's exact upper reporting limit of 1,600,000 copies/mL. Samples from test (two-tailed); the calculations were performed by the SAS subjects whose initially undetectable viral load became detectsystem (version 6.12; SAS Institute, Cary, NC). Multiple logisable following immunization were reassayed (if a surplus of tic regression analysis was used to examine the effect of each the baseline plasma specimen was available) by using a of these factors while controlling for the other factors. Mean branched DNA assay with a sensitivity of 500 copies/mL baseline log plasma HIV-1 RNA values and CD4 cell counts (Chiron Corporation). A §0.48 log (threefold or greater) infor subjects with antibody responses and those without antibody crease above the baseline value was considered clinically sigresponses were compared by using the independent sample t nificant.
test. Four patient groups, defined by the number of antigens to which a significant antibody response developed (none or one, two, or three antigens), were compared by means of analysis
Measurement of Antibody Response
of variance (ANOVA) with a test for linear trend. After completing analysis for the plasma HIV-1 RNA level, remaining plasma samples from 29 of 49 subjects were suffi-Results cient to measure antibody responses at baseline and 2 weeks; 4-week specimens also were available from 12 of 29 subjects.
Subjects
Plasma specimens were shipped frozen to the Influenza Branch, Centers for Disease Control and Prevention for analysis. Anti-
The median age of the 49 study subjects was 39 years; 84% body responses to the three vaccine antigens were measured of the subjects were male, and 49% were Caucasian. Risk by using a standard hemagglutination inhibition (HI) assay factors for acquiring HIV infection included injection drug use [24] . The titers reported here are the reciprocals of the last (41% of subjects), homosexual or bisexual contact (33%), and serum dilution that completely inhibited hemagglutination with heterosexual contact (22%). The mean CD4 cell count { SD a particular antigen. The A/Taiwan/01/86 (H 1 N 1 ) virus, which was 190 { 169/mL (range, 0 -520/mL), and the mean plasma is antigenically related to the A/Texas/36/91 (H 1 N 1 ) vaccine HIV-1 RNA level { SD was 154,616 { 317,192 copies/mL component, was used in this study for measuring responses to (range, õ10,000 to ú1,600,000 copies/mL). Of the subjects, the H1:N1 vaccine component. A fourfold or greater rise from 57% had CD4 cell counts of õ200/mL, 39% had CD4 cell the baseline value after immunization was considered a clinicounts between 201 and 500/mL, and 4% had CD4 cell counts cally significant immune response to vaccination; an HI titer of §501/mL. Seventy six percent of subjects were receiving of §1:40 was considered likely to confer protection. antiretroviral therapy (monotherapy or combination therapy with ZDV, ddI, or ddC).
Since blood samples were to be obtained from subjects during regular clinic visits, specimens from visits after week 2 Increases in plasma HIV-1 RNA levels of §0.48 log occurred in six (12%) of 49 subjects over the 20-week period of were categorized as 4-, 8-, and 12-week specimens, representing samples gathered during weeks 3 -6, 7 -11, and 12 -20, observation (1 at 2 weeks, 1 at 4 weeks, 2 at 8 weeks, and 2 at 12 weeks). Three of six elevations in plasma HIV-1 RNA respectively. Because the distribution of plasma HIV-1 RNA in the sample was skewed and some samples contained ex-levels (1 at 2 weeks, 1 at 8 weeks, and 1 at 12 weeks) were sustained for the remainder of the study period, one was ob-tremely high levels, statistical analyses of plasma HIV-1 RNA levels were based on log-transformed data.
served for only one interval, and the other two fluctuated significantly over subsequent visits. Five of six subjects with sig-The first set of analyses focused on changes in plasma HIV-1 RNA levels after vaccination. The entire cohort was analyzed nificantly increased plasma HIV-1 RNA levels were receiving / 9c63$$mr40 02-22-99 13:00:29 cida UC: CID antiretroviral therapy (the mean baseline plasma HIV-1 RNA { 573,734 copies/mL, respectively; P Å .04), but no difference in antibody response was observed between the groups (11 of level { SD for these six subjects was 77,916 { 21,156 copies/mL).
22 subjects receiving therapy vs. two of seven not receiving therapy, respectively; P Å .41). Because most documented increases in plasma HIV-1 levels have been observed within 2 weeks of immunization, we exam-Age. No association between antibody response by HI titer and age in years was seen after stratifying by either mean or ined the 33 subjects with baseline and 2-week samples and found that the mean viral load { SD for the group decreased median age (P Å .46). Plasma HIV-1 RNA levels. An inverse association was ob-from a baseline value of 189,739 { 376,843 copies/mL to 173,133 { 334,350 copies/mL (P Å .06, paired t test). Of the 33 served between baseline plasma HIV-1 RNA level and the development of a fourfold or greater increase in antibody titer subjects with baseline and 2-week samples, 23 had detectable baseline plasma HIV-1 RNA levels, allowing for comparison in response to at least one vaccine antigen, with the 13 subjects with antibody responses having a lower mean plasma HIV-1 at 2 weeks with a true baseline value (in contrast to an assigned value of 10,000 copies/mL for the 10 subjects with undetectable RNA level { SD than the 16 subjects without antibody responses (38,926 { 47,624 vs. 260,716 { 403,685 copies/mL, baseline plasma HIV-1 RNA levels). Only one of 23 subjects had a fourfold or greater increase at 2 weeks. Of the 10 subjects respectively; P õ .005). When subjects were stratified by baseline plasma HIV-1 RNA level, six (75%) of eight with plasma with undetectable plasma HIV-1 RNA levels at baseline, three had measurable levels at 2 weeks (mean level { SD, 13,246
HIV-1 RNA levels of õ10,000 copies/mL responded as compared with six (50%) of 12 with plasma HIV-1 RNA levels of { 979 copies/mL). When baseline plasma specimens from these three subjects were reanalyzed by using a branched DNA 10,000 -100,000 copies/mL and only one (11%) of nine with plasma HIV-1 RNA levels of ú100,000 copies/mL (P Å .034). assay with a sensitivity of 500 copies/mL, none had a §0.48 log increase above the more sensitive baseline value (mean When plasma HIV-1 RNA levels were stratified by §50,000 and õ50,000 copies/mL, the response rates were 20% (three level { SD, 8,523 { 3,868 copies/mL).
There were 20 subjects for whom plasma HIV-1 RNA levels of 15 subjects) and 71% (10 of 14), respectively (P Å .009). When plasma HIV-1 RNA levels were stratified by the limits were measured during all five periods following vaccination. When mean viral loads were analyzed over time by ANOVA, of detection (õ10,000 or ú10,000 copies/mL), there was a trend toward an undetectable level being associated with a no significant differences (P Å .935) were noted. fourfold or greater increase in HI titer (six of eight subjects vs. seven of 21, respectively; P Å .092). An inverse trend was Antibody Response also seen between the baseline plasma HIV-1 RNA level and the number of antigens to which a significant antibody response Plasma samples for 29 subjects were available for HI assay developed (P Å .02 for the overall difference between means were analyzed according to each of the three vaccine antigens.
by ANOVA, with a significant linear trend of P Å .02). A fourfold or greater rise in HI titer in response to at least one CD4 cell count. The 13 patients with a fourfold or greater antigen was seen by 4 weeks in 13 (45%) of the subjects; 12 increase in HI titer had higher mean baseline CD4 cell counts of these responses occurred by week 2 (table 1). When the 13 { SD than did the 16 subjects without antibody responses subjects with antibody responses were analyzed according to (272 { 143 vs. 99 { 122/mL, respectively; P Å .004). After antigen, fourfold or greater increases in HI titers were observed stratifying by CD4 cell count (õ100 and §100/mL), the rein response to 21 (54%) of 39 possible antigens (10, A/Taiwan/ sponse rates were 8% (one of 12 subjects) and 71% (12 of 17, 01/86 [H 1 N 1 ]; 6, A/Shangdong/09/93 [H 3 N 2 ]; and 5, B/Panrespectively; P Å .002). CD4 cell counts also correlated with ama/45/90). No patient with a fourfold or greater rise in antithe number of vaccine antigens to which a significant antibody body titer in response to any antigen had a §0.48 log increase response developed: patients who responded to no antigens had in plasma HIV-1 RNA level following immunization. a mean CD4 cell count { SD of 99 { 31/mL, and patients Rates of baseline protection against the three vaccine antigens with responses to one, two, and three antigens had higher mean were as follows: 31%, A/Taiwan/01/86 (H 1 N 1 ); 7%, A/Shang-CD4 cell counts { SD of 251 { 61, 292 { 81, and 305 { dong (H 3 N 2 ); and 97%, B/Panama/45/90. After subjects with pro-35/mL, respectively (P Å .02 for the overall difference between tective levels at baseline were excluded, additional protection to means by ANOVA, with a significant linear trend of P Å .05). the antigens developed in 9 (45%) of 20 subjects, 6 (22%) of 27 subjects, and 0 of 1 subject, respectively (table 1). all methods tested, CD4 cell count was the most important vaccinees in our cohort had a significant increase in plasma HIV-1 RNA levels within 4 weeks of vaccination. One of these predictor of antibody response, with plasma HIV-1 RNA levels contributing little after controlling for CD4 cell count (table elevations was sustained for 10 weeks, but this increased level may have been confounded by discontinuation of antiretroviral 2). After controlling for CD4 cell count and plasma HIV-1 RNA levels, antiretroviral treatment also did not contribute. therapy at the time of immunization. Unfortunately, data on the use of antiretroviral therapy are There was a trend toward a negative association between age and immune response that did not reach significance not included in several studies that have demonstrated increased viral load following vaccination [1, 3, 5, 9, 11]. Of six studies (P Å .073).
Multivariate Analysis Effect of Anti-HIV Treatment, Age, Plasma
demonstrating an increase in plasma HIV RNA level after vaccination in which most subjects were receiving antiretrovi-Discussion ral therapy, three specified that this treatment consisted of monotherapy or combination therapy with nucleoside ana-Conflicting results have been reported regarding increases in plasma HIV RNA levels following immunization of HIV-logues [2, 6, 10]. By comparison, Fowke and co-workers [13] found no increase in plasma HIV RNA levels in 35 patients infected patients. Of 21 vaccination studies we reviewed in which viral load was quantified, 12 reported an increase in following the administration of influenza virus vaccine and suggested that the use of antiretroviral therapy by 34 of the HIV-1 expression after vaccination [1 -12], and nine showed no increase [13 -22] . Only two (4%) of 49 influenza virus patients (only two of whom were receiving protease inhibitors) / 9c63$$mr40 02-22-99 13:00:29 cida UC: CID Numerous reports have demonstrated a correlation between CD4 cell count or disease stage and antibody response to various vaccines [15, 16, 25 -28] . In contrast, while plasma HIV RNA levels have been predictors of response to antiretroviral may have contributed to this result. No increases in plasma HIV RNA levels in HIV-infected children who received influ-therapy and to outcomes such as progression to AIDS and mortality [29 -31] , few data are available regarding the correla-enza virus vaccine were observed by Jackson and co-workers [18], but again antiretroviral therapy was not specified.
tion of HIV RNA levels with immune response to vaccination. Both low CD4 cell count and high plasma HIV-1 RNA level The interval between vaccine administration and the first measurement of viral load after vaccination may be contribut-were associated with an impaired immune response to influenza immunization by univariate analysis in our study. Patients with ing to the apparently conflicting data regarding vaccine-related upregulation. In addition to our data, we reviewed 21 pre-CD4 cell counts of ú100/mL were more likely to develop a significant antibody response than were those whose counts viously reported vaccination studies of HIV-infected patients in which quantitation of plasma HIV RNA was done within 1 were õ100/mL (P Å .002). In addition, patients with lower viral loads were more likely than patients with higher viral month of vaccination. Eleven studies showed significant increases in plasma HIV RNA levels [1 -11], while 11 did not loads to develop a significant antibody response: 75% of patients with plasma HIV-1 RNA levels of õ10,000 copies/mL (present report [12 -21] ). When studies were evaluated by the time when plasma specimens were drawn, 11 studies obtained responded compared with 50% with levels of 10,000 -100,000 copies/mL and 11% with levels of ú100,000 copies/mL samples £7 days after vaccination [1 - 6, 9 -11, 14, 20] , while the remaining 11 obtained samples 14 -28 days after immuniza-(P Å .034). We also explored several multivariate models to assess the interaction between CD4 cell count, plasma HIV-1 tion. Nine of 11 ''early sample'' studies showed increases in plasma HIV RNA levels [1 -6, 9 -11], while only two of 11 RNA level, age, and anti-HIV treatment on the response to vaccination. In all models tested, CD4 cell count was a stronger ''late sample'' studies showed increases [7, 8] . Since return of an elevated plasma HIV RNA level to the baseline value has predictor of antibody response than was viral load or the use of antiretroviral therapy. been reported as early as 14 days after vaccination, studies (including ours) in which postvaccination increases in plasma
In assessing the risk-benefit ratio for the use of influenza virus vaccine by HIV-infected patients, the risk of acquiring HIV RNA levels were not observed may have simply ''missed the action'' by measuring plasma HIV RNA levels after they influenza, the natural history of influenza in HIV-infected patients, and the morbidity and mortality associated with influ-had returned to baseline values.
Even if undocumented increases had occurred before mea-enza must be considered. Cohen and Macauley [32] found no cases of influenza in seven HIV-seropositive residents of a surements of plasma HIV RNA levels in the studies with negative results, the absence of an increase during the ''late sam-drug treatment program at the same time that influenza was observed in 14 of 37 HIV-seronegative coresidents. Although pling period'' provides reassurance that most increases are transient. However, brief increases in plasma HIV RNA levels these data suggest that HIV-infected persons are not at an increased risk of acquiring influenza during an outbreak, other are not always the case. Three studies reported rises that did not return to baseline values until 1 -3 months (or longer) data indicate that when acquired, influenza virus infection may have a modified natural history in the context of HIV infection. after vaccination, although no adverse clinical outcomes were associated with these increases [2, 5, 6].
For example, although Safrin and co-workers [33] saw no differences in the clinical presentation and rate of secondary com-Several reports have suggested that an increase in the HIV RNA level following vaccination is correlated with the ability plications of infection due to wild-type influenza virus between HIV-positive and -negative individuals, there was a high preva-of the host to develop an antibody response [2, 4, 6], while / 9c63$$mr40 02-22-99 13:00:29 cida UC: CID
